Considering that the targeting of programmed death ligand 1 (PD-L1) has shown promise in patients with advanced NSCLC [13–15], we evaluated the association between PKM2 and PD-L1 in lung adenocarcinoma. This evidence concerns the gene PKM and non-small cell lung carcinoma.